Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING

CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer

NCT05210283 · View on ClinicalTrials.gov ↗

Study Summary

The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Maximum duration of participant participation is up to seven years from enrollment to study completion with up to five years of active follow up and up to two years of clinical (passive) follow up.

Conditions Studied

Interventions

  • DEVICE MRD

Study Locations (20)

Florida

  • University of Florida Division of Hematology & Oncology — Gainesville
  • Mount Sinai Medical - Comprehensive Cancer Center — Miami Beach
  • Mid Florida Cancer Centers — Orange City

Maryland

  • MedStar Georgetown Cancer Institute at MedStar Georgetown University Hospital — Baltimore
  • Meritus Center for Clinical Research — Hagerstown
  • University of Maryland St. Joseph Medical Center — Towson

North Carolina

  • Atrium Health Levine Cancer Institute — Charlotte
  • FirstHealth Outpatient Cancer Center — Pinehurst
  • Atrium Health Wake Forest Baptist Medical Center — Winston-Salem

California

  • Facey Medical Group - Mission Hills - Endoscopy Center & Gastroenterology — Mission Hills
  • Torrance Memorial Hunt Cancer Institute — Torrance

Illinois

  • Edward Cancer Center — Elmhurst
  • Illinois Cancer Care — Peoria

Iowa

  • Mercy Medical Center — Cedar Rapids

Kansas

  • University of Kansas Cancer Center — Westwood

Minnesota

  • Metro Minnesota Community Oncology Consortium (MMCORC) — Saint Louis Park

Trial Details

FieldValue
Enrollment Target 1,017 participants
Start Date 2021-12-15
Est. Completion 2027-05-15

Sponsor

Exact Sciences Corporation

42 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05210283

The ClinicalTrials.gov registry entry for NCT05210283 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,017 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exact Sciences Corporation, which has 42 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention — of which MRD is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05210283 reports 20 study locations spanning 12 distinct geographic areas — top geographies include Florida, Maryland, North Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05210283 about?

NCT05210283 is a clinical study titled "CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer". The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Maximum duration of participant participation is up to seven years from enrollment to study completion with up to five years of active follow up and up ...

What is the current status of trial NCT05210283?

This trial is currently active not recruiting. The enrollment target is 1,017 participants. The study started on 2021-12-15. Estimated completion is 2027-05-15.

What conditions does trial NCT05210283 study?

This clinical trial studies the following conditions: Colorectal Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05210283?

The interventions under investigation include: MRD (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05210283?

This trial is sponsored by Exact Sciences Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05210283 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial